ALKS Stock Analysis: Buy, Sell, or Hold?
ALKS - Alkermes Inc. plc
$34.96
1.07 (3.16%)
▲
5d:
+5.59%
30d:
+24.95%
90d:
+13.43%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 11, 2026
8d
Get Alerted When ALKS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALKS shows positive signals but monitor for confirmation. Market pricing in 6.3% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ALKS shows positive signals but monitor for confirmation. Market pricing in 6.3% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$34.55
Based on 3.5% avg growth
INTRINSIC VALUE TODAY
$21.45
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALKS is currently trading at $34.96, which is considered extended relative to its 30-day fair value range of $28.57 to $33.48. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.1) compared to its historical average (14.2). At these levels, the market is pricing in 6.3% annual earnings growth.
Technical Outlook: Technically, ALKS is in a uptrend. The price is approaching resistance at $35.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ALKS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.75 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALKS is in a uptrend. The price is approaching resistance at $35.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ALKS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $43.75 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$28.57 -
$33.48
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.0%
Protect Your Profits
ALKS is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 25.1% below Wall St target ($43.75)
- BULLISH: Expecting earnings turnaround to 6.3% growth with 4.2% revenue growth
Fair Price Analysis
30-Day Fair Range
$28.57 -
$33.48
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$31.09
Resistance Level
$35.30
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
17.06
Wall Street Target
$43.75
(+25.1%)
Revenue Growth (YoY)
4.2%
Earnings Growth (YoY)
-12.1%
Profit Margin
22.3%
Valuation Premium vs History
+6.3% premium
PE vs Historical
17.1 vs 14.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.3%
(market-implied from PE analysis)
1-Year Target
$37.16
(+6%)
2-Year Target
$39.50
(+13%)
3-Year Target
$41.99
(+20%)
3-Yr Target (if PE normalizes)
(PE: 17→14)
PE COMPRESSION
$34.95
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 3.0%)
$49.90
(+43%)
Base:
(SPY PE: 17.1, Growth: 3.0%)
$38.19
(+9%)
Bear:
(PE: 14.2, Growth: 3.0%)
$31.78
(-9%)
📈
Valuation based on Current Earnings
Trailing PE: 16.87 | Current EPS (TTM): $2.01
Bull Case
$38.01
(+12%)
Analyst growth 1.9%, PE expands to 18.6
Base Case
$34.55
(+2%)
Market implied 1.9%, PE stable at 16.9
Bear Case
$23.05
(-32%)
Severe decline -20.0%, PE contracts to 14.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 02, 2026 4:37 PM ET
Data refreshes hourly during market hours. Next update: 5:37 PM
Data refreshes hourly during market hours. Next update: 5:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALKS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Craig C Hopkinson
SELL
9000 shares
2025-10-15
Featured in Portfolios
ALKS is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 60 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 54 HOLD |
Advanced ALKS Option Strategies
Professional options setups generated by AI based on today's ALKS price and gamma walls.
